Oral manifestations after COVID-19 vaccination

A 38‐year‐old Thai woman developed painful oral lesions lasting over 8 weeks. The lesions appeared 1 week following the administration of the first dose of AZD1222 vaccine.
Her extraoral examination was unremarkable. The intraoral examination revealed generalized desquamative epithelium, erythematous areas along the marginal gingivae and alveolar mucosa. Pseudomembranes, and erosions and ulceration on the buccal gingiva subjacent to the maxillary and mandibular teeth, and the right lingual dorsum could be seen. Furthermore, generalized desquamative epithelium of the alveolar mucosa of the anterior mandibular teeth as well as the right mandibular and left maxillary posterior molars extending to the mucobuccal folds were present. Erythematous areas also extended from the lingual gingiva of anterior mandibular teeth onto the floor of mouth.
The histopathologic and direct immunofluorescence examination confirmed a diagnosis of pemphigus. After treatment with a potent topical steroid, fluocinolone acetonide 0.05% mouthwash, for one week, her painful oral lesions regressed.

A 28-year-old Thai woman was referred to the Oral Medicine Clinic at the Dental Hospital, Faculty of Dentistry, Naresuan University, with a 6-week history of oral mucosal discomfort and burning sensations that had developed one week following the administration of the second dose of mRNA COVID-19 vaccine (BNT162b2, Pfizer/BioNTech). In addition, the patient had suffered from flu-like symptoms for two days immediately after the vaccination. The extraoral examination was unremarkable. However, the intraoral examination revealed white papular and striated bilaterally of the buccal mucosa and tongue. A biopsy at the left buccal mucosa was taken, and the histopathological findings confirmed a diagnosis of Oral Lichen planus (OLP, a T-cell-mediated inflammatory disease involving mucocutaneous). Routine serological investigations for hepatitis B, hepatitis C, and HIV were unremarkable. The patient was prescribed a topical steroid, fluocinolone acetonide 0.1% in orabase paste, for two weeks, which significantly improved her symptoms. OLP was previously demonstrated after several vaccines including Janssen's Ad26.COV2.S. 

A 34-year-old male patient experienced malaise, high fever, weakness, tender gums, gingival hypertrophy, rashes on the mucous membrane of the oral cavity and halitosis the day after receiving the second dose of the Moderna COVID vaccine. His previous dose was administered 6 months before receiving the second dose without side effects. The patient took no medications, was a nonsmoker and had no history of oral conditions. 

Objective examination revealed lesions on the boundary between the Vermilion border, the mucous membrane and the gingival area of teeth. The gingiva in the area of the anterior teeth was edematous. The teeth were covered with dental plaque, as the patient could not brush his teeth due to tender gingiva. The possible differential diagnosis for the lesion included drug-induced conditioned enlargement or undiagnosed systemic disorders

A microbiome study showed that vaccination increased oral bacterial diversity. This, however, is not always beneficial. 


REFERENCES

Heboyan A, Karobari MI, Marya A. Possible oral manifestation after vaccination against COVID-19: a case report. Oxf Med Case Reports. 2022 Dec 16;2022(12):omac136. doi: 10.1093/omcr/omac136. PMID: 36540847; PMCID: PMC9759947.

Alrawashdeh HM, Al-Habahbeh O, Naser AY, Abu Serhan H, Hamdan O, Sweiss K, Aldalameh Y. Lichen Planus Eruption Following Oxford-AstraZeneca COVID-19 Vaccine Administration: A Case Report and Review of Literature. Cureus. 2022 Feb 27;14(2):e22669. doi: 10.7759/cureus.22669. PMID: 35386174; PMCID: PMC8967128.

Troeltzsch M, Gogl M, Berndt R, Troeltzsch M. Oral lichen planus following the administration of vector-based COVID-19 vaccine (Ad26.COV2.S). Oral Dis. 2022 Nov;28 Suppl 2:2595-2596. doi: 10.1111/odi.14025. Epub 2021 Sep 30. PMID: 34543493; PMCID: PMC8661663.

Kaomongkolgit R, Sawangarun W. Oral lichen planus following mRNA COVID-19 vaccination. Oral Dis. 2022 Nov;28 Suppl 2:2622-2623. doi: 10.1111/odi.14182. Epub 2022 Mar 22. PMID: 35263820; PMCID: PMC9115415.

Thongprasom K, Pengpis N, Phattarataratip E, Samaranayake L. Oral pemphigus after COVID-19 vaccination. Oral Dis. 2022 Nov;28 Suppl 2:2597-2598. doi: 10.1111/odi.14034. Epub 2021 Oct 7. PMID: 34582621; PMCID: PMC8662146.

Hertel M, Schmidt-Westhausen AM, Wendy S, Heiland M, Nahles S, Preissner R, Preissner S. Onset of Oral Lichenoid Lesions and Oral Lichen Planus Following COVID-19 Vaccination: A Retrospective Analysis of about 300,000 Vaccinated Patients. Vaccines (Basel). 2022 Mar 20;10(3):480. doi: 10.3390/vaccines10030480. PMID: 35335112; PMCID: PMC8951494.

Uehara O, Abiko Y, Nagasawa T, Morikawa T, Hiraki D, Harada F, Kawano Y, Toraya S, Matsuoka H, Paudel D, Shimizu S, Yoshida K, Asaka M, Furuichi Y, Miura H. Alterations in the oral microbiome of individuals with a healthy oral environment following COVID-19 vaccination. BMC Oral Health. 2022 Mar 3;22(1):50. doi: 10.1186/s12903-022-02093-6. PMID: 35241064; PMCID: PMC8892109.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more